rhPro-UK

Phase 3Small molecule

TTasly Biopharmaceuticals Co., Ltd.

rhPro-UK is one of 58 small molecule programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Ischemic StrokeActive, not recruiting

StrokePhase 3

Active, not recruiting

Ischemic StrokePhase 3

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Activase

Roche

Preclinical

19 2

rhPro-UK

TTasly Biopharmaceuticals Co., Ltd.

Phase 3

2 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Pradaxa

3 7

Zantac 150

CChattem

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Direct Anticoagulant

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Not yet recruiting

Stroke

NCT07389460

Clinical

Trials by Indication[1]

Stroke2 trials

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

Completed·TTasly Biopharmaceuticals Co., Ltd.·Phase 3·NCT05700591·1,552 enrolled

Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)

Not yet recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 3·NCT07389460·820 enrolled

Ischemic stroke1 trial

Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial

Completed·TTasly Biopharmaceuticals Co., Ltd.·Phase 3·NCT03578822·149 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for rhPro-UK. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rhPro-UK compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rhPro-UK. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tasly Biopharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTasly Biopharmaceuticals Co., Ltd.

rhPro-UK

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Stroke2 trials

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News